FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386865670> ?p ?o ?g. }

• W4386865670 abstract "The Escherichia coli-produced human papillomavirus (HPV) 16/18 bivalent vaccine (Cecolin) has received prequalification by the World Health Organization based on its high efficacy and good safety profile. We aimed to evaluate the immunogenicity and safety of the second-generation nonavalent HPV 6/11/16/18/31/33/45/52/58 vaccine (Cecolin 9) through the randomized, blinded phase 2 clinical trial. Eligible healthy women aged 18–45 years were randomly (1:1) allocated to receive three doses of 1.0 mL (270 µg) of Cecolin 9 or placebo with a 0-1-6-month schedule. The primary endpoint was the seroconversion rate and geometric mean titer of neutralizing antibodies (nAbs) one month after the full vaccination course (month 7). The secondary endpoint was the safety profile including solicited adverse reactions occurring within 7 d, adverse events (AEs) occurring within 30 d after each dose, and serious adverse events (SAEs) occurring during the 7-month follow-up period. In total, 627 volunteers were enrolled and randomly assigned to Cecolin 9 (n = 313) or placebo (n = 314) group in Jiangsu Province, China. Almost all participants in the per-protocol set for immunogenicity (PPS-I) seroconverted for nAbs against all the nine HPV types at month 7, while two failed to seroconvert for HPV 11 and one did not seroconvert for HPV 52. The incidence rates of total AEs in the Cecolin 9 and placebo groups were 80.8% and 72.9%, respectively, with the majority of them being mild and recovering shortly. None of the SAEs were considered related to vaccination. In conclusion, the E.coli-produced 9-valent HPV (9vHPV) vaccine candidate was well tolerated and immunogenic, which warrants further efficacy studies in larger populations." @default.
• W4386865670 created "2023-09-20" @default.
• W4386865670 creator A5003739931 @default.
• W4386865670 creator A5005471950 @default.
• W4386865670 creator A5007727175 @default.
• W4386865670 creator A5017960444 @default.
• W4386865670 creator A5018907834 @default.
• W4386865670 creator A5021634528 @default.
• W4386865670 creator A5026617513 @default.
• W4386865670 creator A5028939852 @default.
• W4386865670 creator A5033560825 @default.
• W4386865670 creator A5035217294 @default.
• W4386865670 creator A5040120584 @default.
• W4386865670 creator A5040515577 @default.
• W4386865670 creator A5046909412 @default.
• W4386865670 creator A5047549409 @default.
• W4386865670 creator A5049757250 @default.
• W4386865670 creator A5053716970 @default.
• W4386865670 creator A5056252854 @default.
• W4386865670 creator A5060310839 @default.
• W4386865670 creator A5061441139 @default.
• W4386865670 creator A5066716873 @default.
• W4386865670 creator A5071672663 @default.
• W4386865670 creator A5076011780 @default.
• W4386865670 creator A5076118607 @default.
• W4386865670 creator A5076419705 @default.
• W4386865670 creator A5078732636 @default.
• W4386865670 creator A5082267036 @default.
• W4386865670 creator A5089174006 @default.
• W4386865670 date "2023-09-01" @default.
• W4386865670 modified "2023-10-18" @default.
• W4386865670 title "Immunogenicity and safety of an Escherichia coli-produced human papillomavirus (types 6/11/16/18/31/33/45/52/58) L1 virus-like-particle vaccine: a phase 2 double-blind, randomized, controlled trial" @default.
• W4386865670 cites W1991451517 @default.
• W4386865670 cites W2039745983 @default.
• W4386865670 cites W2160498668 @default.
• W4386865670 cites W2162320594 @default.
• W4386865670 cites W2586227482 @default.
• W4386865670 cites W2781943803 @default.
• W4386865670 cites W2945441427 @default.
• W4386865670 cites W2991407564 @default.
• W4386865670 cites W2995167300 @default.
• W4386865670 cites W3008715056 @default.
• W4386865670 cites W3010535837 @default.
• W4386865670 cites W3034547816 @default.
• W4386865670 cites W3044920462 @default.
• W4386865670 cites W3204615344 @default.
• W4386865670 cites W4223574449 @default.
• W4386865670 cites W4293087863 @default.
• W4386865670 cites W4293678035 @default.
• W4386865670 cites W4297102952 @default.
• W4386865670 doi "https://doi.org/10.1016/j.scib.2023.09.020" @default.
• W4386865670 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37743201" @default.
• W4386865670 hasPublicationYear "2023" @default.
• W4386865670 type Work @default.
• W4386865670 citedByCount "0" @default.
• W4386865670 crossrefType "journal-article" @default.
• W4386865670 hasAuthorship W4386865670A5003739931 @default.
• W4386865670 hasAuthorship W4386865670A5005471950 @default.
• W4386865670 hasAuthorship W4386865670A5007727175 @default.
• W4386865670 hasAuthorship W4386865670A5017960444 @default.
• W4386865670 hasAuthorship W4386865670A5018907834 @default.
• W4386865670 hasAuthorship W4386865670A5021634528 @default.
• W4386865670 hasAuthorship W4386865670A5026617513 @default.
• W4386865670 hasAuthorship W4386865670A5028939852 @default.
• W4386865670 hasAuthorship W4386865670A5033560825 @default.
• W4386865670 hasAuthorship W4386865670A5035217294 @default.
• W4386865670 hasAuthorship W4386865670A5040120584 @default.
• W4386865670 hasAuthorship W4386865670A5040515577 @default.
• W4386865670 hasAuthorship W4386865670A5046909412 @default.
• W4386865670 hasAuthorship W4386865670A5047549409 @default.
• W4386865670 hasAuthorship W4386865670A5049757250 @default.
• W4386865670 hasAuthorship W4386865670A5053716970 @default.
• W4386865670 hasAuthorship W4386865670A5056252854 @default.
• W4386865670 hasAuthorship W4386865670A5060310839 @default.
• W4386865670 hasAuthorship W4386865670A5061441139 @default.
• W4386865670 hasAuthorship W4386865670A5066716873 @default.
• W4386865670 hasAuthorship W4386865670A5071672663 @default.
• W4386865670 hasAuthorship W4386865670A5076011780 @default.
• W4386865670 hasAuthorship W4386865670A5076118607 @default.
• W4386865670 hasAuthorship W4386865670A5076419705 @default.
• W4386865670 hasAuthorship W4386865670A5078732636 @default.
• W4386865670 hasAuthorship W4386865670A5082267036 @default.
• W4386865670 hasAuthorship W4386865670A5089174006 @default.
• W4386865670 hasBestOaLocation W43868656701 @default.
• W4386865670 hasConcept C121608353 @default.
• W4386865670 hasConcept C126322002 @default.
• W4386865670 hasConcept C142724271 @default.
• W4386865670 hasConcept C159047783 @default.
• W4386865670 hasConcept C159654299 @default.
• W4386865670 hasConcept C168563851 @default.
• W4386865670 hasConcept C197934379 @default.
• W4386865670 hasConcept C203014093 @default.
• W4386865670 hasConcept C203092338 @default.
• W4386865670 hasConcept C204787440 @default.
• W4386865670 hasConcept C22070199 @default.
• W4386865670 hasConcept C2522874641 @default.
• W4386865670 hasConcept C27081682 @default.
• W4386865670 hasConcept C2777451964 @default.
• W4386865670 hasConcept C2778220009 @default.
• W4386865670 hasConcept C2778580637 @default.

• next